Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Analysts cut forecasts at BOC on margin fears: Shares fall at industrial gases and healthcare group

Alison Eadie
Thursday 11 August 1994 18:02 EDT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

SHARES in BOC, the industrial gases and healthcare group, fell 31p to 714p on evidence of margin pressure in the third quarter.

Stockbroking analysts trimmed profits forecasts. Kleinwort Benson, already at the lower end of the range, lopped pounds 10m off this year's forecast to pounds 340m pre-tax and pounds 10m off next year's to pounds 380m pre-tax. BOC made pounds 337.6m pre-tax profit in the year to September 1993.

Operating profits in the nine months to the end of June fell by just under 1 per cent to pounds 323.6m.

Gases profits rose 5 per cent in the nine months and 10 per cent in the third quarter, but strong volume growth in the US, where margins are historically lower, led to a narrowing of margins.

The healthcare division was the main disappointment, with operating profits dropping 42 per cent. The company said the cause was generic competition for Forance anaesthetic following its patent expiry. The new anaesthetic Suprane continued to achieve market penetration, but analysts expressed worries about the cost of bringing it to market.

Vacuum technology and distribution achieved a 61 per cent jump in operating profits to pounds 36.8m, enjoying strong demand, especially from the semiconductor industries in the US and Pacific region.

BOC says it is on target with its restructuring programme. It is aiming to take pounds 8m in costs out of gases and pounds 12m out of healthcare this year. The programme accounted for an pounds 85m exceptional charge.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in